Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074085 | 0.94 | HTT (0.55) | ALDH1A1HTTP2RX7KMT2ATP53 | |
| SCHEMBL4246819 | 0.80 | P2RX7 (0.54) | SMN1; SMN2ALDH1A1POLBHTTP2RX7 | |
| SCHEMBL3557506 | 0.79 | P2RX7 (0.53) | ALDH1A1POLBP2RX7KMT2ARAB9A | |
| SCHEMBL7934893 | 0.78 | P2RX7 (0.53) | ALDH1A1POLBP2RX7KMT2ARAB9A | |
| SCHEMBL29594946 | 0.78 | TRPV1 (0.72) | SMN1; SMN2ALDH1A1KMT2ATP53HPGD | |
| SCHEMBL4074090 | 0.77 | P2RX7 (0.40) | ALDH1A1HTTP2RX7KMT2ATP53 | |
| SCHEMBL4079697 | 0.77 | SMN1; SMN2 (0.75) | SMN1; SMN2ALDH1A1HTTKMT2ARAB9A | |
| SCHEMBL7905467 | 0.76 | F13A1 (0.53) | ALDH1A1RAB9ATP53 | |
| SCHEMBL20672330 | 0.75 | F13A1 (0.56) | — | |
| SCHEMBL11867707 | 0.75 | ALDH1A1 (0.58) | ALDH1A1HTTP2RX7KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | SMN1; SMN2 1061/4885ALDH1A1 158/4885POLB 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.